久久婷婷国产综合精品,久久久久久久性潮,换脸国产av一区二区三区,韩国精品一区二区三区无码视频 ,久久久久成人精品无码

  • Jounce Therapeutics Receives FDA Clearance of Investigational NDA for Anti-CCR8 Antibody americanpharmaceuticalreview
    June 17, 2021
    Jounce Therapeutics Inc., a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, announced the U.S. FDA's clearance of its Investigational New Drug (IND) application for JTX-1811 ...
  • Celgene licenses antibody JTX-8064 from Jounce for $50m pharmaceutical-technology
    July 25, 2019
    Global biopharma company Celgene has updated its 2016 strategic collaboration with clinical stage-focused Jounce Therapeutics and has decided to license global rights to JTX-8064; Celgene will now be responsible for all development and commercialisation o
PharmaSources Customer Service